Brief: Quince Therapeutics Existing Cash Position To Provide Operating Runway Through Phase 3 Topline Results Into 2026
24/03/2025 20:49
March 24 (Reuters) - Quince Therapeutics Inc QNCX.O: QUINCE THERAPEUTICS: EXISTING CASH POSITION TO PROVIDE OPERATING RUNWAY THROUGH PHASE 3 TOPLINE RESULTS INTO 2026 Source text: ID:nBwbKmjh9a Further company coverage: QNCX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges